Michael R. Bishop, MD, on impactful lymphoma research presented at ASH 2021

Michael R. Bishop, MD, discussed details of the ZUMA-7 and TRANSFORM trials that were presented at the ASH 63rd Annual Meeting.

Michael R. Bishop, MD, professor of medicine and director of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, spoke with CancerNetwork® at the 2021 Annual Meeting of the American Society of Hematology on some key upcoming research on lymphoma.

Bishop addressed both the TRANSFORM (NCT03575351)1 and ZUMA-7 studies (NCT03391466),2 studying lisocabtagen maraleucel for relapsed/refractory aggressive non-Hodgkin’s lymphoma eligible for transplant and axicabtagen ciloleucel (Yescarta) for relapsed/refractory diffuse large B-cell lymphoma, respectively.

Transcription:

I will come back to the ZUMA-7 and TRANSFORM [trials]. We expected similar results [in our trial]3 to what has been seen of these [trials]. The results of these 2 trials could change the practice in terms of applying CAR T cells earlier in [the treatment] to treat. There is a very nice editorial [in the] New England Journal of Medicine that accompanied our article and the ZUMA-7 trial trying to look at these 3 studies and some of the factors that come into play [applying CAR T-cells earlier in treatment], but it shows that there is a distinction. What I took away from this is that for at least those patients with refractory primary recurrence and early relapse, CAR T cells appear to provide a treatment option that improves progression-free survival and a potential suggestion for overall survival. . [advantage], and that it is an important treatment option. The question [that has] what about second-line patients who relapse beyond 12 months? This is a controversial area. There is an argument that autologous transplantation would still be the standard of care and that CAR T cells would be an option for them down the line. There is also the school of thought among many researchers that results from ZUMA-7 and TRANSFORM can be extrapolated and applied to patients beyond 12 months. I know that both companies have set up a [NDA] at the FDA. They seek to obtain an indication for a second-line treatment in a large patient population. It remains to be seen whether or not the FDA takes this last argument, but hopefully we at least have it as an indication from the FDA for these patients. [who relapse in 12 months or less].

The references

  1. Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19 antigen receptor (CAR)-directed chimeric T-cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by transplant Autologous Stem Cells (ASCT) as Second-Line (2L) Treatment in Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study . Blood 2021;138(suppl 1):91.doi:10.1182/blood-2021-147913
  2. Locke FL, Miklos DB, Jacobson C, et al. Primary Analysis of ZUMA-7: A Randomized Phase 3 Trial Comparing Axicabtagene Ciloleucel (axi-cel) to Standard Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma. Blood 2021;138(supplement 1):2. doi:10.1182/sang-2021-148039
  3. Bishop MR, Dickinson M, Purtill D et al. Tisagenlecleucel vs standard therapy as second-line therapy for refractory or relapsed primary aggressive B-cell non-Hodgkin’s lymphoma: analysis of the phase III Belinda study. Blood 2021;138(supplement 2):LBA-6. doi:10.1182/sang-2021-155068

Comments are closed.